These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 27068887

  • 1. Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials.
    Celis-Aguilar E, Hinojosa-González R, Vales-Hidalgo O, Coutinho-Toledo H.
    Braz J Otorhinolaryngol; 2016; 82(6):668-673. PubMed ID: 27068887
    [Abstract] [Full Text] [Related]

  • 2. Single-shot, low-dose intratympanic gentamicin in Ménière disease: role of vestibular-evoked myogenic potentials and caloric test in the prediction of outcome.
    Gode S, Celebisoy N, Akyuz A, Gulec F, Karapolat H, Bilgen C, Kirazli T.
    Am J Otolaryngol; 2011; 32(5):412-6. PubMed ID: 20851502
    [Abstract] [Full Text] [Related]

  • 3. Intratympanic gentamicin injection for refractory ménière's disease (MD) has potential effect in preventing contralateral MD occurrence.
    Wu Y, Zhou Y, Yu J, Song Z, Dai C, Wang J.
    Acta Otolaryngol; 2021 Jul; 141(7):657-662. PubMed ID: 33950779
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Ménière's disease by low-dosage intratympanic gentamicin application: effect on otolith function.
    Helling K, Schönfeld U, Clarke AH.
    Laryngoscope; 2007 Dec; 117(12):2244-50. PubMed ID: 17909448
    [Abstract] [Full Text] [Related]

  • 5. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.
    Wu IC, Minor LB.
    Laryngoscope; 2003 May; 113(5):815-20. PubMed ID: 12792316
    [Abstract] [Full Text] [Related]

  • 6. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy.
    Minor LB.
    Am J Otol; 1999 Mar; 20(2):209-19. PubMed ID: 10100525
    [Abstract] [Full Text] [Related]

  • 7. The Follow-Up Role of the Vestibular Evoked Myogenic Potential Test in Meniere's Disease.
    Yazdani N, Nejadian F, Rezazadeh N, Hoseinabadi R, Karimi E, Gharibi R, Dabiri S.
    Acta Med Iran; 2018 Jan; 56(1):43-48. PubMed ID: 29436794
    [Abstract] [Full Text] [Related]

  • 8. Intratympanic gentamicin for intractable Meniere's disease.
    Perez N, Martín E, García-Tapia R.
    Laryngoscope; 2003 Mar; 113(3):456-64. PubMed ID: 12616197
    [Abstract] [Full Text] [Related]

  • 9. Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease.
    Bodmer D, Morong S, Stewart C, Alexander A, Chen JM, Nedzelski JM.
    Otol Neurotol; 2007 Dec; 28(8):1140-4. PubMed ID: 18084826
    [Abstract] [Full Text] [Related]

  • 10. Intratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo.
    Carey J.
    Otolaryngol Clin North Am; 2004 Oct; 37(5):1075-90. PubMed ID: 15474112
    [Abstract] [Full Text] [Related]

  • 11. Intratympanic gentamicin treatment of patients with Ménière's disease with normal hearing.
    Silverstein H, Wazen J, Van Ess MJ, Daugherty J, Alameda YA.
    Otolaryngol Head Neck Surg; 2010 Apr; 142(4):570-5. PubMed ID: 20304280
    [Abstract] [Full Text] [Related]

  • 12. Intratympanic gentamicin injections for Meniere disease: vestibular hair cell impairment and regeneration.
    De Waele C, Meguenni R, Freyss G, Zamith F, Bellalimat N, Vidal PP, Tran Ba Huy P.
    Neurology; 2002 Nov 12; 59(9):1442-4. PubMed ID: 12427902
    [Abstract] [Full Text] [Related]

  • 13. Intratympanic gentamicin treatment for Meniere's disease.
    McFeely WJ, Singleton GT, Rodriguez FJ, Antonelli PJ.
    Otolaryngol Head Neck Surg; 1998 May 12; 118(5):589-96. PubMed ID: 9591855
    [Abstract] [Full Text] [Related]

  • 14. Management of intractable Ménière's disease after intratympanic injection of gentamicin.
    Rah YC, Han JJ, Park J, Choi BY, Koo JW.
    Laryngoscope; 2015 Apr 12; 125(4):972-8. PubMed ID: 25363447
    [Abstract] [Full Text] [Related]

  • 15. Factors relating to the vertigo control and hearing changes following intratympanic gentamicin for intractable Ménière's disease.
    Horii A, Saika T, Uno A, Nishiike S, Mitani K, Nishimura M, Kitahara T, Fukushima M, Nakagawa A, Masumura C, Sasaki T, Kizawa K, Kubo T.
    Otol Neurotol; 2006 Sep 12; 27(6):896-900. PubMed ID: 16788414
    [Abstract] [Full Text] [Related]

  • 16. Reliability of the vestibular evoked myogenic potential test in assessing intratympanic gentamicin therapy in Meniere's disease.
    Ozluoglu LN, Akkuzu G, Ozgirgin N, Tarhan E.
    Acta Otolaryngol; 2008 Apr 12; 128(4):422-6. PubMed ID: 18368577
    [Abstract] [Full Text] [Related]

  • 17. Auditory results after vestibular nerve section and intratympanic gentamicin for Ménière's disease.
    Colletti V, Carner M, Colletti L.
    Otol Neurotol; 2007 Feb 12; 28(2):145-51. PubMed ID: 17255880
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of vestibular evoked myogenic potentials (VEMP) and electrocochleography for the diagnosis of Ménière's disease.
    Lamounier P, de Souza TSA, Gobbo DA, Bahmad F.
    Braz J Otorhinolaryngol; 2017 Feb 12; 83(4):394-403. PubMed ID: 27397722
    [Abstract] [Full Text] [Related]

  • 19. Low-dose intratympanic gentamicin and the treatment of Meniere's disease: preliminary results.
    Driscoll CL, Kasperbauer JL, Facer GW, Harner SG, Beatty CW.
    Laryngoscope; 1997 Jan 12; 107(1):83-9. PubMed ID: 9001270
    [Abstract] [Full Text] [Related]

  • 20. Does intratympanic gentamicin treatment for Meniere's disease cause complete vestibular ablation?
    Hone SW, Nedzelski J, Chen J.
    J Otolaryngol; 2000 Apr 12; 29(2):83-7. PubMed ID: 10819105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.